201 related articles for article (PubMed ID: 30444838)
21. Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial.
Byrne C; Pareek M; Vaduganathan M; Biering-Sørensen T; Qamar A; Pandey A; Olesen TB; Olsen MH; Bhatt DL
Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):356-363. PubMed ID: 31529024
[TBL] [Abstract][Full Text] [Related]
22. Effect of intensive blood pressure lowering on cardiovascular outcomes based on cardiovascular risk: A secondary analysis of the SPRINT trial.
Attar A; Sayadi M; Jannati M
Eur J Prev Cardiol; 2019 Feb; 26(3):238-245. PubMed ID: 30256671
[TBL] [Abstract][Full Text] [Related]
23. Systolic and diastolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension and pre-frailty or frailty status.
Zhu J; Yang K; Liu W
J Clin Hypertens (Greenwich); 2024 May; 26(5):514-524. PubMed ID: 38552135
[TBL] [Abstract][Full Text] [Related]
24. Applicability and cost-effectiveness of the Systolic Blood Pressure Intervention Trial (SPRINT) in the Chinese population: A cost-effectiveness modeling study.
Li C; Chen K; Cornelius V; Tomeny E; Wang Y; Yang X; Yuan X; Qin R; Yu D; Wu Z; Wang D; Chen T
PLoS Med; 2021 Mar; 18(3):e1003515. PubMed ID: 33661907
[TBL] [Abstract][Full Text] [Related]
25. Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study.
Rodriguez CJ; Swett K; Agarwal SK; Folsom AR; Fox ER; Loehr LR; Ni H; Rosamond WD; Chang PP
JAMA Intern Med; 2014 Aug; 174(8):1252-61. PubMed ID: 24935209
[TBL] [Abstract][Full Text] [Related]
26. Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials.
Basu S; Sussman JB; Rigdon J; Steimle L; Denton BT; Hayward RA
PLoS Med; 2017 Oct; 14(10):e1002410. PubMed ID: 29040268
[TBL] [Abstract][Full Text] [Related]
27. Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events.
Rathi N; Whelton PK; Chertow GM; Cushman WC; Cheung AK; Wei G; Boucher R; Kimmel PL; Bress AP; Kramer HJ; Al-Marji C; Greene T; Beddhu S
Am J Hypertens; 2019 Nov; 32(12):1170-1177. PubMed ID: 31257407
[TBL] [Abstract][Full Text] [Related]
28. Remnant cholesterol and intensive blood pressure control in older patients with hypertension: a post hoc analysis of the STEP randomized trial†.
Yang R; Zhang J; Yu X; Yang G; Cai J
Eur J Prev Cardiol; 2024 Jun; 31(8):997-1004. PubMed ID: 38167928
[TBL] [Abstract][Full Text] [Related]
29. Diastolic Hypotension May Attenuate Benefits from Intensive Systolic Targets: Secondary Analysis of a Randomized Controlled Trial.
Lee TC; Cavalcanti RB; McDonald EG; Pilote L; Brophy JM
Am J Med; 2018 Oct; 131(10):1228-1233.e1. PubMed ID: 29906425
[TBL] [Abstract][Full Text] [Related]
30. The relationship of all-cause mortality to average on-treatment systolic blood pressure is significantly related to baseline systolic blood pressure: implications for interpretation of the Systolic Blood Pressure Intervention Trial study.
Okin PM; Kjeldsen SE; Devereux RB
J Hypertens; 2018 Apr; 36(4):916-923. PubMed ID: 29176391
[TBL] [Abstract][Full Text] [Related]
31. Effects of Intensive Blood Pressure Control in Patients with Evident Cardiovascular Disease: An Investigation Using the SPRINT Study Data.
Vlachopoulos C; Terentes-Printzios D; Aznaouridis K; Ioakeimidis N; Xaplanteris P; Lazaros G; Tousoulis D
Curr Vasc Pharmacol; 2019; 17(3):298-306. PubMed ID: 29512468
[TBL] [Abstract][Full Text] [Related]
32. Baseline Diastolic Blood Pressure and Cardiovascular Outcomes in SPRINT Participants with Chronic Kidney Disease.
Chang TI; Wei G; Boucher R; Kramer H; Chertow GM; Cheung AK; Greene T; Whelton PK; Beddhu S
Kidney360; 2020 May; 1(5):368-375. PubMed ID: 35369376
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Hypertension: Which Goal for Which Patient?
Jarraya F
Adv Exp Med Biol; 2017; 956():117-127. PubMed ID: 27722961
[TBL] [Abstract][Full Text] [Related]
34. Effects of Intensive Systolic Blood Pressure Lowering on Cardiovascular Events and Mortality in Patients With Type 2 Diabetes Mellitus on Standard Glycemic Control and in Those Without Diabetes Mellitus: Reconciling Results From ACCORD BP and SPRINT.
Beddhu S; Chertow GM; Greene T; Whelton PK; Ambrosius WT; Cheung AK; Cutler J; Fine L; Boucher R; Wei G; Zhang C; Kramer H; Bress AP; Kimmel PL; Oparil S; Lewis CE; Rahman M; Cushman WC
J Am Heart Assoc; 2018 Sep; 7(18):e009326. PubMed ID: 30371182
[TBL] [Abstract][Full Text] [Related]
35. Modification of the effects of intensive systolic blood pressure control on kidney outcomes by baseline body mass index.
Agarwal A; Wei G; Boucher R; Ahmed F; Beddhu S
Nephrology (Carlton); 2021 Apr; 26(4):303-311. PubMed ID: 33538091
[TBL] [Abstract][Full Text] [Related]
36. Systolic Blood Pressure Response in SPRINT (Systolic Blood Pressure Intervention Trial) and ACCORD (Action to Control Cardiovascular Risk in Diabetes): A Possible Explanation for Discordant Trial Results.
Huang C; Dhruva SS; Coppi AC; Warner F; Li SX; Lin H; Nasir K; Krumholz HM
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29133522
[TBL] [Abstract][Full Text] [Related]
37. Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.
Böhm M; Schumacher H; Teo KK; Lonn E; Mahfoud F; Mann JFE; Mancia G; Redon J; Schmieder R; Weber M; Sliwa K; Williams B; Yusuf S
Eur Heart J; 2018 Sep; 39(33):3105-3114. PubMed ID: 29873709
[TBL] [Abstract][Full Text] [Related]
38. Clinical benefit of systolic blood pressure within the target range among patients with or without diabetes mellitus: a propensity score-matched analysis of two randomized clinical trials.
Li C; Chen K; Shi G; Shi R; Wu Z; Yuan X; Watson V; Jiang Z; Mai H; Yang T; Wang D; Chen T
BMC Med; 2022 Jun; 20(1):208. PubMed ID: 35718771
[TBL] [Abstract][Full Text] [Related]
39. J-shaped relationship between cardiovascular risk and efficacy of intensive blood pressure reduction: A post-hoc analysis of the SPRINT trial.
Attar A; Nouri F; Borazjani R; Sayadi M
PLoS One; 2020; 15(10):e0240102. PubMed ID: 33002071
[TBL] [Abstract][Full Text] [Related]
40. Orthostatic changes in systolic blood pressure among SPRINT participants at baseline.
Townsend RR; Chang TI; Cohen DL; Cushman WC; Evans GW; Glasser SP; Haley WE; Olney C; Oparil S; Del Pinto R; Pisoni R; Taylor AA; Umanath K; Wright JT; Yeboah J;
J Am Soc Hypertens; 2016 Nov; 10(11):847-856. PubMed ID: 27665708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
